Clarithromycin-statin mix can cause drug interactions, requiring hospitalization

The combination of the common antibiotic clarithromycin with some statins increases the risk of adverse events, which may require hospital admission for older people, according to a new study. Statins, used to lower cholesterol, are one of the most widely prescribed drugs, with projections estimated at more than 1 billion people around the globe. Although uncommon, severe adverse events can occur in some patients when certain medications interact with the statin and affect the way it is metabolized.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Source: Patient Preference and Adherence - Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Purpose of review The goal of this review is to present recent models of the filtration barrier that may suggest mechanism-based treatments for proteinuric renal disease. The vast majority of renal failure occurs in diseases of glomerular proteinuria. The physiology of the filtration barrier remains incompletely understood, preventing invention of mechanism-based therapies. Research is currently dominated by molecular biology approaches to the kidney instead of engineering-based filtration and transport models. Recent findings Reexamination of two older paradigms (basement membrane and slit diaphragm) and critical ana...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: RENAL IMMUNOLOGY AND PATHOLOGY: Edited by Agnes B. Fogo Source Type: research
People who initiate statins or antihypertensive medicines are more likely to become obese or physically inactive compared with people who do not, a study published in the  Journal of the American Heart Association suggests. 
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Statins are the only Class I ISHLT recommendation in heart transplantation (HT) as an established therapy to reduce cardiac allograft vasculopathy (CAV) and improve survival. However, the goal LDL is not known with no formal recommendation on targets. We assessed if LDL
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (553) Source Type: research
Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplant (LT) Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have shown to have immunomodulatory and antiinflamatory effects unrelated to their cholesterol-lowering function. We hypothesized that recipient's preoperative statin therapy is associated with decreased incidence of PGD after LT.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (383) Source Type: research
This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV) and related outcomes of rejection and mortality after cardiac transplant in the setting of tacrolimus as primary calcineurin inhibitor.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (508) Source Type: research
In this study, we analyzed myocardial gene expression profiles in cardiac allografts after donor simvastatin treatment.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (192) Source Type: research
Left ventricular (LV) global longitudinal strain (GLS) is a robust marker of subclinical myocardial dysfunction. Previous studies showed that as small as 2% reduction in GLS predicted major adverse event in heart transplant (HT) recipients, including cardiac allograft vasculopathy (CAV). Although low intensity statin is commonly used after HT to reduce CAV, the incremental impact of statin intensity on myocardial function is unknown.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (616) Source Type: research
ConclusionsStatin initiators had a lower risk of any ALI outcome compared with non-users within 18  months regardless of HIV and/or HCV status.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
As yet there's no magic bullet that offers protection against coronavirus. And even though vitamin C supplements are selling in huge quantities, hard evidence on its effectiveness is lacking.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Biaxin | Cholesterol | Clarithromycin | Hospitals | Science | Statin Therapy | Study